Apr 30 |
Merrimack Pharmaceuticals announces notification of plan to delist common stock on Nasdaq
|
Apr 30 |
Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution
|
Mar 27 |
Merrimack receives $225M milestone payment from Ipsen
|
Mar 27 |
Merrimack Receives $225 Million Milestone Payment from Ipsen
|
Mar 7 |
Merrimack Pharmaceuticals reports FY results
|
Mar 7 |
Merrimack Reports Full Year 2023 Financial Results
|
Mar 4 |
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is definitely on the radar of hedge funds investors who own 35% of the company
|
Feb 13 |
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
|
Feb 13 |
Merrimack spikes as Ipsen wins FDA label expansion for cancer therapy
|
Dec 12 |
$2M Bet On Ford? Check Out These 4 Stocks Insiders Are Buying
|